US03168L1052
US03168L1052
Amneal Pharmaceuticals, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 6.93B EUR | 5.53B EUR | 3.97B EUR | 3.96B EUR |
Enterprise Value | 9.02B EUR | 8.19B EUR | 6.46B EUR | 6.37B EUR |
Valuation Multiples | ||||
Trailing P/E | 40.63x | 35.13x | 32.47x | 66.21x |
Forward P/E | 16.7x | -- | -- | -- |
Price to Sales | 2.22x | 1.77x | 1.3x | 1.71x |
Price to Book | 193.3x | 167.38x | -- | -- |
EV/Revenue | 2.89x | 2.63x | 2.12x | 2.74x |
EV/EBITDA | 13.08x | 12.52x | 10.2x | 14.31x |
Price to FCF (P/FCF) | -- | -- | 21.08x | 16.76x |
EV/FCF | -- | -- | 34.37x | 26.93x |
FCF Yield | -1.66% | -0.22% | 4.74% | 5.97% |